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Recent emergence of a third generation of mechanistic
target of rapamycin (mTOR) inhibitors, termed
RapaLink-1, have generated hope in treatment of
glioblastoma, the most aggressive primary brain tumor in
adults. Produced by coupling first and second generation
mTOR inhibitors (1), RapaLink-1 displays superior efficacy
in inhibition of the mTOR complex I (mTORC1) pathway.
This led to the inhibition of proliferation with relatively
longer durability in glioblastoma cells and xenograft models.
Importantly, RapaLink-1 crosses the blood-brain barrier
and effectively targets mutant mTOR glioblastoma cells.
RapaLink-1 is a bivalent inhibitor generated by combining
the analogue inhibitor of mTOR, rapamycin, with the ATPcompetitive inhibitor of mTOR, MLN0128. The resulting
compound is more potent than first- and second-generation
mTOR inhibitors. Investigation by Fan et al. [2017] (1)
examined the effect of RapaLink-1 and RapaLink-2 on
glioblastoma cell growth and proliferation by targeting the
mTORC1.
mTOR is a member of the phosphoinositide 3-kinaserelated kinase (PI3K) family with homologs in all
eukaryotes (2,3). The N-terminus of mTOR contains
several huntingtin elongation factor 3 protein phosphatase
2A TOR1 (HEAT) repeats to facilitate the majority
of interactions with other proteins. The FKB-FRAP
domain that directly binds to rapamycin is located at the
C-terminus of the mTOR protein. The C-terminus also
contains a kinase domain that places it in the PI3K family.
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The canonical PI3K/Akt/mTOR signaling axis regulates
various physiological functions including cellular growth,
proliferation, differentiation, and metabolism (2,4,5).
Hyperactivation of mTOR signaling in cancers occurs
via multiple mechanisms (6) and results in an increase
in cell growth, causing some cell types to enter the cell
cycle. Aberrant mTOR pathway activity is prevalent in
glioblastoma, leading to abnormalities in cell proliferation
and motility, thereby resulting in uncontrolled growth
and dissemination (7,8). Mutations of PTEN are found
in approximately 70–90% of glioblastoma that leads to
deregulation of the PI3K/Akt/mTOR signaling axis. In
addition to frequent deletions and mutations of the tumor
suppressor PTEN, about 86% of the glioblastoma samples
display at least one genetic event leading to activation of the
RTK/PI3K pathway (9). Constitutive activation of mTOR
via single point mutations has been shown in many cancers,
including glioblastoma (10). Hyper-activation of mTOR
signaling makes it an attractive target for therapeutic
intervention. In fact, first-generation mTOR inhibitors,
rapamycin, and its analogue, rapalogs, exclusively bind to
the component of mTORC1 and inhibit mTOR activity
with limited success in clinical settings. Among these
agents, first-generation mTOR inhibitors, rapamycin, and
its analogue, rapalogs, inhibit mTOR by forming a complex
with the immunophilin FKBP12. FKBP12 then exclusively
binds directly to the component of mTORC1 (4). Second
generation ATP-competitive inhibitor of mTOR shows
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Figure 1 Schematic representation of mTOR structure showing FRB and kinase domains (11), where novel bivalent mTOR inhibitor
RapaLink binds, which is created by linking analogue inhibitor rapamycin and ATP-competitive inhibitor MLN0128 to the regions of FRB
and kinase of mTOR, respectively (1). Also shown in this figure are two multiprotein complexes of mTOR, mTORC1 and mTORC2 (see
text for details). mTOR, mechanistic target of rapamycin; mTORC, mTOR complex 1.

potent and selective inhibition of mTORC1 and mTORC2.
It also shows anti-proliferative activity, however, it is limited
in suppressing mTORC1. Resistant glioblastoma cells as
well as therapy related formation of mutant mTOR were
the major obstacles of mTOR inhibitors.
Creation of RapaLink, the third generation of
mTOR complex inhibitors, was achieved by linking first
generation analogue binding inhibitor, rapamycin, to the
second generation inhibitor, MLN0128, hence termed,
RapaLink (Figure 1). Two forms of RapaLink were created:
RapaLink-1 and Rapalink-2, which differ in size of linker
length. RapaLink-1was superior in inhibiting mTOR
complex as it potently reduced levels of both p-4EBP1, an
important component of mTORC1, and cell proliferation
as compared with RapaLink-2. RapaLink-1 was shown
to be more potent in inhibiting glioblastoma cell growth
inhibition as well as halting cells in G0/G1 of the cell
cycle as compared to rapamycin or MLN0128 alone. As
expected, rapamycin suppressed the mTORC1 target,
p-RPS6S235/236, and MLN0128 inhibited both the mTORC1
targets p-RPS6 S235/236 and p-4EBP1 T37/46 , as well as
mTORC2 targets p-AKTS473 in a dose-dependent manner.
In this investigation, Fan et al. [2017] (1) demonstrated
that RapaLink-1 selectively inhibited p-RPS6 S235/236 and
p-4EBP1T37/46 at a low dose of 1.56 nM. Suppression of
mTORC2 was achieved at higher doses only in two human
glioblastoma cell lines, LN229 and U87MG, and in short-
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term primary cultures from patient-derived xenografts. It is
important to note that glioblastoma may develop new driver
mutations in response to therapies, including activating
mutations in mTOR itself. Crucially, RapaLink-1 effectively
reduced cell proliferation of glioblastoma cells expressing
either wild-type or activating mutation of mTOR, namely
mTORR2505P and mTORS2115Y. Rapamycin treatment also
caused a significant suppression in cell growth irrespective
of mTOR status, albeit to a lesser extent as compared to
RapaLink-1. On the other hand, MLN0128 treatment was
less effective in cells expressing mutant mTOR. Fan et al.
[2017] (1) further demonstrated that RapaLink-1 blocked
activation of p-4EBP1T37/46 regardless of mutational status of
mTOR. In contrast, levels of p-4EBP1T37/46 remained higher
in mTOR mutant glioblastoma cells treated with rapamycin
or MLN08. These results strengthened the effectiveness of
RapaLink-1 as compared to first- and second-generation
mTOR inhibitors.
Rapamycin and its chemically related compounds have
recently been used in clinical trials for the treatment
of cancer due to their inhibitory effects on the mTOR
pathway (12). Clinical trials using rapamycin and its
analogs (CCI-779/temsirolimus, RAD001/everolimus, and
AP23573) have shown promising yet challenging results in
the management of various tumors including glioblastoma.
In fact, a trial by Cloughesy et al. [2008] (13) showed that
rapamycin successfully reduced tumor growth in half of
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the patients with PTEN-deficient, recurrent glioblastoma.
However, there were challenges in targeting the mTOR
pathway as a significant number of patients showed an
increased level of phosphorylated AKT and PRAS40. It
was concluded that this activation could be due to loss
of negative feedback, resulting in decreased time for
progression free-survival in these patients, causing poor
clinical outcomes (13). This particular trial stands out as it
demonstrates the molecular mechanisms of glioblastoma
developing resistance to rapamycin and its analogs.
Specifically, this trial establishes the limited therapeutic
effectiveness of mTOR inhibition with rapamycin and its
analogs due to loss of negative feedback. Therefore, despite
significant advancement in targeted therapy, glioblastoma
remains incurable possibly in part due to activation of
mitogenic pathways such as RAS/ERK1/2 (7,8). Preclinical
and clinical studies of ATP-competitive mTOR inhibitors
that target both mTORC1 and mTORC2 demonstrated
greater effectiveness than rapalogs in treatment of cancer.
However, it is important to consider that the acute
mTORC1 inhibition can activate the negative feedback
loop leading to triggering of PI3K/PDK1/Akt (Thr308)
and IRS1 via mitogenic pathways, leading to relentless cell
survival and proliferation (7,8).
In vivo studies performed in mTOR xenograft models
using BALB/Cnu/nu mice, administered daily I.P. injections
of vehicle, MLN0128, rapamycin, or RapaLink-1 every
5th day, showed that RapaLink-1 inhibited components
of mTORC1, p-RPS6S235/236 and p-4EBP1T37/46 in a dosedependent manner in the brain. Conversely, it failed to
inhibit the mTORC2 substrate p-AKT S473 in vivo. An
important observation of this study was that RapaLink
crosses through the blood-brain barrier (1). Furthermore,
experiments revealing tumor burden, mTOR signaling, and
survival analysis revealed that RapaLink-1 caused regression
and subsequent stabilization of tumor size. In contrast
vehicle, rapamycin, or MLN0128-treated mice displayed
a steady growth in their tumor. Furthermore, RapaLink-1
blocked the expression of p-4EBP1T37/46 while MLN0128
or rapamycin had modest effects in reducing the levels of
p-4EBP1T37/46. Suppression of p-RPS6S235/236 was achieved
in all treatment groups individually, however inhibition
of mTORC2 substrate p-AKTS473 was achieved only after
treatment with MLN0128.
Further in this study, xenograft/mice-treated with
inhibitors were followed for survival/analyses, which
showed that RapaLink-1 treated animals had much
improved survival as compared to vehicle, MLN012,
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or rapamycin-treated animals. In addition, proliferative
index was robustly suppressed by RapaLink-1 treatment
whereas it was only modestly suppressed by rapamycin
or MLN0128 treatments. Authors further demonstrated
that patient-derived glioblastoma cells in xenograft models
displayed a marked reduction in tumor growth following IP
administration of RapaLink-1 when analyzed by luciferase
signal as compared with vehicle, rapamycin, or MLN0128
treatments (1). As with earlier treatments, RapaLink-1
efficiently blocked the expression of p-4EBP1 T37/46 in
tumors, while both MLN0128 and rapamycin only
modestly reduced p-4EBP1T37/46. Levels of p-RPS6S235/236
remained indistinctly suppressed by all treatments and
MLN0128 exclusively inhibited p-AKTS473. Structurally,
binding of rapamycin to FKBP12 and FRAP is subjected
to two different hydrophobic binding pockets which helps
occupancy of rapamycin in cells leading to a sustained
suppression of mTORC1 substrate, p-RPS6 S235/236 (14).
Fan et al. [2017] (1) showed that RapaLink-1 compared
with both rapamycin and MLN0128 was most effective in
suppressing human glioma cell growth for a long period of
time and phosphorylation of RPS6 and 4EBP1 was downregulated over a period of 24 h.
First and second generation inhibitors of mTOR
displayed incomplete effects in glioblastoma tumors in both
preclinical and clinical studies. Rapamycin and its analogues
allosteric inhibitors inhibit mTORC1 by targeting S6K
without inhibiting 4EBP1 (15). On the other hand,
MLN0128 was more effective than rapamycin in in vitro
studies, as it was able to inhibit mTORC1 target 4EBP1,
but displayed shorter residence time (16). An improved
efficacy of RapaLink-1 in in vivo studies may be attributed to
its ability to efficiently block 4EBP1 as well as its prolonged
residence time. Furthermore, in glioblastoma, 4EBP1is
considered as a more reliable marker for mTORC1 activity
and therefore inhibition of 4EBP1 is crucial in suppressing
mTOR activity (17). RapaLink-1 treated cells showed
higher levels of FKBP12 bound compared with cells treated
with rapamycin. The rapamycin-FKBP12 complex binds
only to FRB, whereas the RapaLink-1-FKBP12 complex
binds to FRB and to the mTOR kinase domain, thereby
increasing affinity as well as stability leading to higher
efficacy. Despite its size, RapaLink-1 was able to cross the
blood-brain barrier and induce regression of tumor burden
in orthotopic/xenograft models for brain cancer. This class
of agents thus holds promise for future therapy of patients
with glioblastoma.
While RapaLink-1 promoted regression in glioblastoma
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models, this initial regression was followed by regrowth
of the tumor. Such recurrence is consistent with data
suggesting that mTOR inhibitors as monotherapies are
not sufficient to achieve anti-tumor responses in most
cancers (6). Studies to establish the basis for recurrence,
such as induction of autophagy, negative feedback loops,
rewiring, or acquisition of resistance by emergence of novel
mutations will determine the means that promote apoptosis
and overcome resistance to position RapaLink-1 for clinical
development in treatment of glioblastoma.
The mTORC1 complex is composed of proteins such as
regulatory associated protein of mTOR (RAPTOR), which
is sensitive to rapamycin treatment. It has been shown that
mTORC1 function is tightly regulated by PI3K/AKT. In
contrast to mTORC1, the mTORC2 complex is sensitive
to growth factors but not nutrients, and is associated with
the rapamycin-insensitive companion of mTOR (RICTOR)
along with other proteins (11). The major distinguishing
characteristic of the mTORC1 and mTORC2 is their
differential sensitivity to rapamycin (5). mTORC1 regulates
protein synthesis through phosphorylating its downstream
substrates, 4EBP1 (also called EIF4EBP1) and p70
S6K1/2 (11). The mTOR-dependent phosphorylation
of p70 S6K1/2 promotes translation initiation as well as
elongation and regulates cellular growth (11). mTORC2
modulates growth factor signaling by phosphorylating the
C-terminal hydrophobic motif of some AGC kinases, such
as AKT and SGK. Pharmacological inhibition of these
complexes has been difficult to achieve. A phase I trial
of rapamycin in PTEN-deficient glioblastoma patients
showed some promising results with inherent difficulties
of targeting mTOR pathways. A significant number of
patients showed increased activated levels of pAKT Ser473
following rapamycin treatment, which was correlated with
shorter time to progression. The observed AKT activation
was likely due to an alteration of signaling feedback loops,
highlighting the complexity of prolonged rapamycin
treatment.
Rapamycin (sirolimus) and its analogs, RAD001
(everolimus) and CCI-779 (temsirolimus), suppress
mTOR activity through an allosteric mechanism that acts
at a distance from the ATP binding catalytic site. Major
disadvantages of rapamycin and other related compounds
are that it suppresses TORC1 mediated S6K activation,
thereby blocking a negative feedback loop. This led to the
activation of PI3K/AKT and Ras/MEK/ERK signaling
pathways, promoting cell survival and growth. Rapamycin
remains an incomplete inhibitor of mTORC1 (18). In recent
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years, novel small ATP binding site molecules have been
identified that directly inhibit mTOR, unlike rapamycin,
which is an allosteric inhibitor of mTOR. In addition,
novel ATP binding compounds with pyrazolopyrimidines
are shown to inhibit members of the PI3K family,
including mTOR. One such compound, PP242, is an ATPcompetitive inhibitor of mTOR, which shows potent and
selective inhibition of mTORC1 and mTORC2 (19). These
molecules are often phrased “TORKinibs” for their ability
to inhibit TOR kinase. First-generation TORi compounds
such as PP242 inhibits mTORC1/C2 in AKT/mTOR
signaling. Novel MLN0128, a second-generation of TORi
compound (20), appears to be more potent.
Limitations of rapalogs-based clinical strategies have
pushed toward the development of a second generation of
mTOR inhibitors known as ATP-competitive mTOR kinase
inhibitors (TORKIs), which target the kinase domain of
mTOR and inhibit its catalytic activity. From a mechanistic
point of view, the advantage of these drugs relies on the
ability of inhibiting the kinase activity of both the TORC1
and TORC2 complexes while also blocking the feedback
activation of PI3K/Akt signaling (18,21,22). Combinatory
strategies may provide a way to overcome such resistance
and therefore improve efficacy of mTOR targeting agents
in the clinical context (23). In addition, mTOR has also
been involved in regulation of stem cells (3).
The development of a third generation of mTOR
inhibitors, such as RapaLink-1, holds the potential to
overcome the resistance to the rapaloge or TORKi, perhaps
due to its ability to bind to two drug-binding pockets of
mTOR (Figure 1). As demonstrated in breast cancer cells,
RapaLink-1 has the ability to target MCF-7 cells that
carried three somatic mutations within mTOR, FRBFKBP1, or Kinase domain conferring resistance (24). It is
important to realize that the hyperactive M2327I mutation
as seen here, similar to other mTOR kinase domain
mutations, are seen in patients with no prior treatments (25),
which may influence the sensitivity to ATP-competitive
mTOR inhibitors. While FRB-domain mutations can
cause resistance to therapy by disrupting the interaction
of FKBP12-rapamycin complex to mTOR, influencing
the binding of the inhibitor, the Kinase domain mutations
cause hyperactivation of the kinase activity. Marked by
such challenges, a drug-modeling technique has created a
novel bivalent mTOR inhibitor such as Rapalink. Rapalink
consists of a rapamycin-FRB-binding compound linked
to a TORKi, which can target both FRB-domain as well
as Kinase domain of mTOR. RapaLink potently inhibits
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the mTORC1 pathway by inhibiting the phosphorylation
of 4EBP1 and growth inhibition both in vitro and in vivo,
at levels comparable to rapamycin or a combination of
rapamycin with MLN0128. Importantly, RapaLink-1also
targets cells expressing specific mTOR mutations.
In summary, inhibition of the mTOR pathway following
bivalent kinase inhibitor has proven to be therapeutic
for glioblastoma and future clinical studies are expected
to reveal the significance of such unique approaches. It
is not unreasonable to envision that such therapeutic
options may be effective in successfully treating patients
with hyperactive mTOR kinase domain mutations and/or
those who have developed resistance to rapalogs or ATPcompetitive inhibitors. Future clinical trials may suggest
whether RapaLink-1 results in therapy related resistance
or activates alternate pathways due to the loss of negative
feedback. Nevertheless, it is worth noting that bivalent
kinase inhibitors such as Rapalink-1 are unique in design as
described by Fan et al. (1) to provide more stable and potent
suppressive effects on mTOR pathways in glioblastoma.
Therefore, studies such as those presented here using
novel bivalent inhibitors may serve as the initial foundation
for developing innovative strategies in treatment of fatal
cancers such as glioblastoma.
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